SYNTap® Test For Alzheimer's

Up to 50% of people diagnosed with Alzheimer’s have co-existing Lewy Body Disease associated with misfolded Synuclein. Our SYNTap Test accurately detects this biomarker.

Research supported by:


SYNTap® Test For Alzheimer's

The SYNTap Biomarker Test helps doctors identify Lewy bodies in people with Alzheimer’s. Why is this essential? Research shows up to 50% of Alzheimer’s cases have Lewy bodies at autopsy. Lewy bodies are associated with misfolded Synuclein.

In addition, Lewy bodies and misfolded Synuclein may accelerate the disease progression of Alzheimer’s.

Who should take the SYNTap Test?

  • If you have previously been diagnosed with Alzheimer’s, the SYNTap Biomarker Test helps your doctors identify and differentiate mixed-type dementias.
  • If your doctor suspects a neurodegenerative condition, you need this biomarker test to understand what role, if any, misfolded Synuclein plays.
  • If you have suspicions but have not been diagnosed with Alzheimer’s, this test helps your doctor complete a full workup.

What are the key benefits?

Biomarker testing offers several benefits:

  • Helps physicians distinguish classic Alzheimer’s from other dementias.
  • Reduces the risk of misdiagnosis, leading to more effective treatments.
  • Guides patients to participate in suitable clinical trials.
  • Makes informed life plans to navigate a brain care journey, such as building a care team.
  • Accelerates scientific innovation for drug development. 

Molecular diagnosis is the first step to personalized medicine for treating Alzheimer’s.

How the SYNTap Test works

This test helps doctors identify misfolded Synuclein, a prion protein biomarker to distinguish Alzheimer’s from Lewy Body Dementia or other types of dementia.

After a decade of diligent development in our lab, the test process is now only three steps:

  1. Your doctor orders the test and submits a few drops of your cerebrospinal fluid (CSF),
  2. Our lab tests your sample for misfolded Synuclein,
  3. Your doctor receives the lab result within two weeks.

Why test CSF instead of blood?

CSF testing offers the highest accuracy and reliability. How?

Our research shows that misfolded proteins happen early in the brain. So when they are detectable in blood, it is highly likely that the disease has progressed to a later stage. 

Why is it crucial to differentiate Alzheimer's from LBD?

Alzheimer’s and Lewy Body Dementia are two distinct diseases with overlapping symptoms, especially in the early stages. 

The diseases take unique progression paths, therefore requiring different treatments.  Differentiating them matters greatly. 

Challenges to distinguish AD vs. LBD at early stages

Historically, it has been challenging for physicians to distinguish Alzheimer’s vs. Lewy Body Dementia, especially during the early stages. Here’s why: 

  • Initially, Alzheimer’s patients mainly show a cognitive decline such as loss of memory and executive functions. However, for advanced Alzheimer’s patients, motor symptoms may also appear.
  • Similarly, LBD patients first show comparable cognitive decline. They may also experience visual/olfactory hallucinations, dizziness, constipation, sleep disorders, etc.
  • Like Alzheimer’s, advanced LBD patients may also show motor symptoms, a hallmark of Parkinson’s.
  • The shared symptoms of Alzheimer’s and LBD are strikingly similar before the noticeable movement symptoms start. 

The mixed symptoms make Alzheimer’s and LBD challenging to distinguish early using traditional diagnostics methods.

Harmful consequences of misdiagnosis

Brain diseases can be difficult to diagnose using traditional methods. With biomarker testing, we can now identify the prion biomarkers, helping doctors make accurate diagnoses. 

Alzheimer’s drugs may harm LBD patients and vice versa. Here are three examples:

  • Memantine, a drug commonly used to treat moderate to severe Alzheimer’s, may worsen both cognitive and motor symptoms in LBD patients.
  • Antipsychotic medications used to treat behavioral disorders in Alzheimer’s patients can cause serious side effects in LBD patients.
  • Levodopa, an LBD medication, has little or no cognitive benefit when given to Alzheimer’s patients and may even induce or worsen motor disorders.

The need for proper treatment makes accurate diagnosis even more important. 

Comparing Alzheimer's and LBD biomarkers

  • LBD results from the proliferation of misfolded Synuclein aggregates in the brain. This prion protein causes both cognitive and motor symptoms in LBD patients.
  • In Alzheimer’s, cognitive decline arises from the accumulation of two prion proteins: Misfolded Abeta and Tau.
  • In advanced Alzheimer’s patients may also develop Parkinson’s-like motor symptoms.
  • These late-stage Alzheimer’s symptoms may be associated with misfolded Synuclein or TDP-43, another biomarker.
  • In summary, research shows four prion biomarkers drive the progression in neurodegenerative diseases. They are Misfolded Synuclein, Abeta, Tau, and TDP43. 

Brain diseases can be challenging to diagnose.

Biomarker Testing Can Help.

parkinson's research and care center

Brain diseases can be challenging to diagnose.

Biomarker Testing Can Help.

Alzheimer's Biomarkers

Research shows all Alzheimer’s patients have two types of prions in their brains:

  • Abeta
  • Tau

Furthermore, up to 50% of people with Alzheimer’s show two additional prions:

  • Synuclein
  • TDP43

The biomarker profile of Alzheimer’s patients indicates the type of Alzheimer’s: Classic Alzheimer’s (AD-C) vs. Mixed-type Alzheimer’s (AD-M).

Classic Alzheimer’s

Patients whose brains contain only Abeta and Tau prions are said to have Classic Alzheimer’s or AD-C.

Mixed-type Alzheimer’s

In addition to Abeta and Tau prions in the brains, some Alzheimer’s patients also have Synuclein or TDP43 prions. This condition is referred to as Mixed-Type Alzheimer’s or AD-M.

Classic Alzheimer’s vs. Mixed-type Alzheimer’s

Research studies suggest that patients with Mixed-type Alzheimer’s may progress faster than those with Classic Alzheimer’s.

In addition, AD-M patients with Synuclein prions may have symptoms more closely resembling LBD than those with Classic Alzheimer’s. These AD-M patients may exhibit Lewy bodies at autopsy.

Benefit of the SYNTap Test

The SYNTap Biomarker Test identifies the presence or absence of Synuclein prions in AD-M patients, helping doctors gain clarity in their diagnosis.   


A physician must prescribe the SYNTap® Test. Please complete this short form if you’d like us to contact your doctor.

I’d like Amprion to Contact My Doctor

Please send information about Amprion and the
SYNTap Biomarker Test to my physician:

Full Disclosure:  Amprion has measures in place to protect your privacy, including administrative, technical, and physical safeguards. While Amprion has security measures to protect against the loss, misuse, or alteration of information, it is not possible to guarantee the safety of the information transmitted on the Internet. Therefore, you should use safeguards on the computers you use to access our website to help keep your information secure.

Scroll to Top